Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tobramycin
Drug ID BADD_D02232
Description Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms.[A232294] Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749]
Indications and Usage For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
Marketing Status Prescription; Discontinued
ATC Code J01GB01; S01AA12
DrugBank ID DB00684
KEGG ID D00063
MeSH ID D014031
PubChem ID 36294
TTD Drug ID D07BCT
NDC Product Code 47335-171; 68788-7252; 65162-914; 63187-973; 51927-0226; 68083-312; 49502-401; 0078-0630; 68071-2272; 51927-2375; 53002-9230; 60760-583; 36000-242; 17478-290; 61314-643; 61919-598; 70644-899; 55700-747; 0404-7196; 76420-092; 0078-0494; 0093-4085; 70518-1370; 45865-427; 68180-962; 20076-2006; 42513-0011; 81861-0030; 49502-346; 0065-0644; 51846-1012; 68083-241; 0078-0813; 68071-4537; 51552-1520; 24492-850; 67457-473; 72266-163; 24208-290; 11014-0233; 50090-3569; 67457-428; 0065-0643; 50090-0486; 59651-129; 57885-0002; 68083-254; 53002-9232; 68083-374; 67877-678; 71205-101; 53002-9231; 61919-642; 36000-244; 13985-604; 45865-119; 39822-0412; 63187-024; 70700-173; 49502-345; 11722-073; 72266-196; 68083-253; 17478-340; 0093-3750; 63187-902; 10122-820; 53002-9233; 70069-131
Synonyms Tobramycin | Nebramycin Factor 6 | Tobramycin Sulfate | Sulfate, Tobramycin | Obracin | Tobracin | Brulamycin | Nebcin | Nebicin
Chemical Information
Molecular Formula C18H37N5O9
CAS Registry Number 32986-56-4
SMILES C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Nephropathy toxicLysozyme CP61626T105863820859; 3573418; 2352376; 6519582
Nephropathy toxicL-lactate dehydrogenase A chainP00338T150533820859; 3573418; 2352376; 6519582
Nephropathy toxicBeta-hexosaminidaseP87258Not Available3820859; 3573418; 2352376; 6519582
Toxicity to various agents1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Q9NQ66T26846Not Available
Toxicity to various agentsPhospholipase A2P04054T31479Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bronchitis22.07.01.001; 11.01.09.0010.001857%
Bronchospasm10.01.03.012; 22.03.01.0040.006189%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.008046%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.003--Not Available
Chronic obstructive pulmonary disease22.03.01.0070.001372%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctival oedema06.04.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.0020.001238%
Constipation07.02.02.001--
Corneal abrasion12.01.04.001; 06.11.03.001--Not Available
Cough22.02.03.0010.024448%
Cystic fibrosis22.03.01.015; 07.18.03.001; 03.16.01.0020.006136%Not Available
Deafness04.02.01.0010.004333%Not Available
Death08.04.01.0010.013240%
Dehydration14.05.05.001--
Delirium19.13.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic10.01.03.014; 23.03.04.0030.000619%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diabetes mellitus14.06.01.001; 05.06.01.0010.005880%Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.001238%Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.001--Not Available
Drug interaction08.06.03.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages